Both of these stocks should have plenty of room to run.Are there misconceptions about investing? You bet there are. One of the biggest, in my opinion, is that you need a lot of money to get started. That's not true at all.You can find plenty of affordable stocks that offer solid long-term growth prospects. If you're interested in the healthcare sector, it's an especially easy task. Here are two no-brainer healthcare stocks to buy with $200 right now.Pfizer: A better story than meets the eyeI can imagine som ...

Ian Read, chairman and chief executive officer of Pfizer, speaks as President Donald Trump, left, listens during an announcement on a new pharmaceutical glass packaging initiative in the Roosevelt Room of the White House in Washington, D.C., July 20, 2017.Former Pfizer CEO Ian Read and ex-CFO Frank D'Amelio said Wednesday evening that they would step away from Starboard Value's campaign at the struggling pharmaceutical giant, just days after news of the activist's stake broke.Read and D'Amelio said they wer ...

NEW YORK, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Guggenheim Securities, LLC is issuing a statement on behalf of former Pfizer CEO Ian Read and former Pfizer CFO Frank D’Amelio: We have decided not to be involved in the efforts of Starboard Value regarding Pfizer. We are fully supportive of Pfizer Chairman & CEO Albert Bourla, senior management and the board, and we are confident that over time they will deliver shareholder value. ...

The sharp, sudden entry of an activist investor is raising hopes that change might come to the company.Pfizer (PFE 3.46%) was a stock on the move Wednesday, and not because of any news generated by the healthcare company. Reports of a meeting between Pfizer's leader and an activist investor breathed life into the stock, which closed the day more than 3% higher in price. That gain well exceeded the 0.7% increase of the S&P 500 index.An activist meeting is apparently imminentLate afternoon on Tuesday, the Fin ...

Pfizer (PFE, Financial) experienced a 2.3% increase, reaching $29.85. The rise follows news that Pfizer's CEO plans to meet next week with key leaders from activist investor Starboard Value. Starboard Value currently holds approximately $1 billion in Pfizer stock and is advocating for changes to improve the company's performance.In addition, Pfizer and its German partner BioNTech secured a legal victory in the London High Court, invalidating two patents held by competitor CureVac. The disputed technology un ...

I publish my best ideas and top coverage on the Growth Stock Forum . If you're interested in finding great growth stocks, with a focus on biotech, consider signing up. We focus on attractive risk/reward situations and track each of our portfolio and watchlist stocks closely. To receive e-mail notifications for my public articles and blogs, please click the follow button . And to go deeper, sign up for a free trial to Growth Stock Forum.The story of activist fund Starboard Value taking a $1 billion position ...

Ken Griffin's Citadel continues to add to its position in Pfizer.Each quarter, hedge funds that manage over $100 million are required to file a Form 13F with the Securities and Exchange Commission (SEC). These filings break down which stocks investment firms bought and sold during the most recent quarter.Ken Griffin is a billionaire investor who serves as CEO of the hedge fund Citadel. Last quarter, Citadel bought 7.9 million shares of Pfizer (PFE 0.93%) -- increasing its stake in the pharmaceutical giant b ...

KEY TAKEAWAYSPfizer CEO Albert Bourla reportedly is planning to meet with Starboard Value after the activist investor took a $1 billion stake in the struggling drugmaker.Bourla and at least one other director will hold discussions with Starboard next week, the Financial Times reported, in a sign that the hedge fund’s demands are being taken seriously by the COVID-19 vaccine maker. Pfizer's shares have halved since their pandemic peak in 2021 as demand for its COVID-19 vaccines slumped. Pfizer (PFE) Chief Ex ...

Core Viewpoint - Pfizer's stock has significantly underperformed compared to its peers and the broader market, primarily due to declining revenues post-COVID vaccine demand and overestimation of long-term product demand [1][3]. Group 1: Stock Performance - Pfizer stock currently trades at $29 per share, which is 45% below its peak of $54 in December 2021 [1]. - The stock was at $47 in early June 2022, before the Federal Reserve began increasing interest rates, and is still 40% below that level [1]. - In contrast, Merck's stock has increased by 54% during the same period, while the S&P 500 has gained 50% [1]. Group 2: Recent Developments - Activist investor Starboard Value has acquired a $1 billion stake in Pfizer, likely pushing for strategic changes [2]. - A UK court upheld Pfizer's bid to invalidate two GSK patents related to a respiratory syncytial virus vaccine, which is a positive development for the company [2]. Group 3: Financial Outlook - Pfizer's estimated valuation is around $34 per share, indicating a 15% upside from current levels, based on a projected earnings per share of $2.62 for 2024 [3]. - The company’s revenue rose from $41.7 billion in 2020 to $100.3 billion in 2022, but fell by 42% year-over-year to $58.5 billion in 2023 [8]. - Earnings per share dropped from $1.71 in 2020 to $0.37 in 2023 on a reported basis [8]. Group 4: Debt and Cash Flow - Pfizer's total debt increased from $38 billion in 2020 to $71 billion currently, largely due to the Seagen acquisition [9]. - The company has a cash cushion of approximately $12.7 billion and generated $8 billion in cash flows from operations over the last twelve months, indicating it can meet near-term obligations [9]. Group 5: Future Growth Potential - Despite recent declines, Pfizer is expected to deliver low to mid-single-digit average annual growth in the coming years as market sentiments improve [10]. - The company's high debt level remains a significant challenge to achieving these growth targets [10].

Starboard will look to turn around the struggling pharma company.Shares of Pfizer (PFE -0.07%) have been stuck in the mud since December 2022, with its shares down more than 45% over that stretch. Despite its underwhelming performance, many individual investors are attracted to the drug giant's robust dividend, with the stock now having a forward dividend yield of about 5.7%. And despite its performance, one large institutional investor just revealed a billion-dollar bet on the company.According to the Wall ...